FDA Cancels ODAC Meeting on Two Drugs With Accelerated Approvals; Science Publishes Report Showing Confirmatory Trials Often Don’t Happen for the Drugs

The FDA canceled its scheduled Oncologic Drugs Advisory Committee (ODAC) meeting last week during which it had planned to discuss two cancer drugs that hold accelerated approvals (AA).
Source: Drug Industry Daily